Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience
Severe aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25–30% of patients have a matched sibling donor, and finding an unrelated donor in ethnic minoriti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/3/93 |
| _version_ | 1797241521774264320 |
|---|---|
| author | Vered Stavi Niranjan Khaire Jeffrey H. Lipton Rajat Kumar |
| author_facet | Vered Stavi Niranjan Khaire Jeffrey H. Lipton Rajat Kumar |
| author_sort | Vered Stavi |
| collection | DOAJ |
| description | Severe aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25–30% of patients have a matched sibling donor, and finding an unrelated donor in ethnic minorities is a challenge. The use of related haploidentical donor transplants in severe aplastic anemia is uncommon. We would like to report our experience with the first four patients who underwent haploidentical transplants for severe aplastic anemia. This is a retrospective study. We collected data from our transplant database of all haploidentical hematopoietic stem cell transplants for SAA from 1 January 2020 to 31 December 2021. The transplant protocol used was the Hopkins’ protocol. There were three patients who underwent haploidentical transplants as primary therapy for SAA. A fourth patient received a haploidentical transplant after immunosuppressive therapy failure. The median age of the patients at transplant was 24 y (range 20–29). All patients were engrafted. Neutrophil engraftment occurred at a median of 21 days (range 17–22). Any active infections resolved with the recovery of blood counts. The median hospitalization time was 27 days (range 22–41). Only one patient had grade 2 acute GVHD involving the skin. There was no chronic GVHD. All patients had complete lymphoid and myeloid donor chimerism on day 60. Based on our experience and the emerging literature, haplo-identical transplantation should be considered for select young patients with SAA who have low chances of responding to immunosuppressive therapy. |
| first_indexed | 2024-04-24T18:24:39Z |
| format | Article |
| id | doaj.art-7fd155e966c642559c23ed08b7ffcdfd |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-04-24T18:24:39Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-7fd155e966c642559c23ed08b7ffcdfd2024-03-27T13:32:41ZengMDPI AGCurrent Oncology1198-00521718-77292024-02-013131246125210.3390/curroncol31030093Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre ExperienceVered Stavi0Niranjan Khaire1Jeffrey H. Lipton2Rajat Kumar3Soroka Medical Center, Beer Sheva 84101, IsraelPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, CanadaPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, CanadaPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, CanadaSevere aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25–30% of patients have a matched sibling donor, and finding an unrelated donor in ethnic minorities is a challenge. The use of related haploidentical donor transplants in severe aplastic anemia is uncommon. We would like to report our experience with the first four patients who underwent haploidentical transplants for severe aplastic anemia. This is a retrospective study. We collected data from our transplant database of all haploidentical hematopoietic stem cell transplants for SAA from 1 January 2020 to 31 December 2021. The transplant protocol used was the Hopkins’ protocol. There were three patients who underwent haploidentical transplants as primary therapy for SAA. A fourth patient received a haploidentical transplant after immunosuppressive therapy failure. The median age of the patients at transplant was 24 y (range 20–29). All patients were engrafted. Neutrophil engraftment occurred at a median of 21 days (range 17–22). Any active infections resolved with the recovery of blood counts. The median hospitalization time was 27 days (range 22–41). Only one patient had grade 2 acute GVHD involving the skin. There was no chronic GVHD. All patients had complete lymphoid and myeloid donor chimerism on day 60. Based on our experience and the emerging literature, haplo-identical transplantation should be considered for select young patients with SAA who have low chances of responding to immunosuppressive therapy.https://www.mdpi.com/1718-7729/31/3/93severe aplastic anemiaallogeneic bone marrow transplanthaploidentical donor |
| spellingShingle | Vered Stavi Niranjan Khaire Jeffrey H. Lipton Rajat Kumar Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience Current Oncology severe aplastic anemia allogeneic bone marrow transplant haploidentical donor |
| title | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience |
| title_full | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience |
| title_fullStr | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience |
| title_full_unstemmed | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience |
| title_short | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia—Single-Centre Experience |
| title_sort | haploidentical hematopoietic stem cell transplantation for patients with severe aplastic anemia single centre experience |
| topic | severe aplastic anemia allogeneic bone marrow transplant haploidentical donor |
| url | https://www.mdpi.com/1718-7729/31/3/93 |
| work_keys_str_mv | AT veredstavi haploidenticalhematopoieticstemcelltransplantationforpatientswithsevereaplasticanemiasinglecentreexperience AT niranjankhaire haploidenticalhematopoieticstemcelltransplantationforpatientswithsevereaplasticanemiasinglecentreexperience AT jeffreyhlipton haploidenticalhematopoieticstemcelltransplantationforpatientswithsevereaplasticanemiasinglecentreexperience AT rajatkumar haploidenticalhematopoieticstemcelltransplantationforpatientswithsevereaplasticanemiasinglecentreexperience |